Patel Rakesh, Strimling Robert, Doggett Stephen, Willoughby Mark, Miller Kenneth, Dardick Lawrence, Mafong Erick
Good Samaritan Radiation Oncology, Los Gatos, CA.
Strimling Dermatology, Laser Vein Institute, Las Vegas, NV.
J Contemp Brachytherapy. 2017 Aug;9(4):338-344. doi: 10.5114/jcb.2017.68480. Epub 2017 Jun 23.
High-dose-rate electronic brachytherapy (EBT) provides a non-surgical treatment option for non-melanoma skin cancer (NMSC). This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs micrographic surgery (MMS) in patients with NMSC.
At four treatment centers, patients treated with EBT were case matched to patients treated with MMS based on retrospectively-collected patient age, lesion size, location and type, and year of treatment. Follow-up data were prospectively collected and included local recurrence, toxicities, cosmesis, and patient-reported outcomes.
The 369 patients (188 in the EBT treatment group and 181 in the MMS treatment group) had 416 lesions (208 in the EBT group and 208 in the MMS group), including 226 basal cell carcinomas (BCC) and 190 squamous cell carcinomas (SCC). Most patients were Caucasian (98.9% and 99.5%) and male (65.4% and 66.3%) of median age 80.7 (range: 61-98) (EBT) and 76.8 (range: 51-98) years (MMS). Most lesions were size > 1 cm and ≤ 2 cm, and located on the head. At mean 3.4 years post-treatment, 99.5% of EBT, and 100.0% of MMS-treated lesions were free of recurrence ( = ns). One recurrence was noted in the EBT group. Physicians rated cosmesis as "excellent" or "good" in 97.6% of EBT-treated lesions, and 95.7% of MMS-treated lesions.
This matched-pair cohort study supports the use of EBT as an effective non-surgical treatment option for NMSC with equivalent recurrence rates and cosmetic outcomes to MMS in appropriately-selected patients with early stage NMSC at extended follow-up.
高剂量率电子近距离放射治疗(EBT)为非黑色素瘤皮肤癌(NMSC)提供了一种非手术治疗选择。这项配对队列研究比较了NMSC患者接受EBT治疗与莫氏显微外科手术(MMS)治疗的结果。
在四个治疗中心,根据回顾性收集的患者年龄、病变大小、位置和类型以及治疗年份,将接受EBT治疗的患者与接受MMS治疗的患者进行病例匹配。前瞻性收集随访数据,包括局部复发、毒性反应、美容效果和患者报告的结果。
369例患者(EBT治疗组188例,MMS治疗组181例)有416个病变(EBT组208个,MMS组208个),包括226例基底细胞癌(BCC)和190例鳞状细胞癌(SCC)。大多数患者为白种人(分别为98.9%和99.5%),男性(分别为65.4%和66.3%),EBT组中位年龄80.7岁(范围:61 - 98岁),MMS组中位年龄76.8岁(范围:51 - 98岁)。大多数病变大小>1 cm且≤2 cm,位于头部。治疗后平均3.4年,99.5%接受EBT治疗的病变和100.0%接受MMS治疗的病变无复发(P =无显著性差异)。EBT组有1例复发。医生将97.6%接受EBT治疗的病变和95.7%接受MMS治疗的病变的美容效果评为“优秀”或“良好”。
这项配对队列研究支持在适当选择的早期NMSC患者中,将EBT作为一种有效的非手术治疗选择用于NMSC,其复发率和美容效果与MMS相当,且随访时间延长。